M&T Bank’s Biogen BIIB Stock Holding History

M&T Bank’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-400	Closed	-$20K	–	2105
2015 Q1	$20K	Hold	400	–	–	﹤0.01%	1964
2014 Q4	$7K	Buy	+400	New	+$129K	﹤0.01%	2053

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

M&T Bank's BIIB Position: Q2 2026 in Review

M&T Bank reduced its Biogen (BIIB) stake by 0.86% in Q2 2026, selling an estimated $26.8K and leaving 16,084 shares worth $3.47M. The position accounts for 0.01% of the portfolio, ranked #500.

M&T Bank first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $32.6M in Q1 2015. 1,045 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

M&T Bank held 16,084 shares of Biogen worth $3.47M as of Q2 2026.
M&T Bank sold 140 Biogen shares in Q2 2026, an estimated $26.8K.
Biogen made up 0.01% of M&T Bank's portfolio in Q2 2026, its #500 holding.
M&T Bank first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
M&T Bank's Biogen position peaked at $32.6M in Q1 2015.
1,045 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.